AZ Goes Into The MYSTIC And Finds Positives For Imfinzi

Against all the odds, AstraZeneca still has hopes for Imfinzi in first-line NSCLC with data from the failed MYSTIC trial suggesting strong survival in patients with a high tumour mutation burden.

Detective
Searching for clues in mystic • Source: Shutterstock

Less than a month after confirming its closely-watched MYSTIC lung cancer trial of Imfinzi (durvalumab) plus tremelimumab had failed, AstraZeneca PLC has presented the full results from the study which suggest that there may still be a place for the PD-L1 inhibitor as a first-line treatment for the disease.

In November, AstraZeneca confirmed that in MYSTIC, Imfinzi in combination with the firm's investigational anti-CTLA-4 antibody tremelimumab improved neither overall...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immuno-oncology

More from Anticancer